37 reports

  • INTRODUCTION
  • INTERVIEW TRANSCRIPTS

MANY SUCH LENSES ARE BEING EVALUATED FOR THE CONTROLLED DELIVERY OF THE OPHTHALMIC DRUGS AND IMPROVING OCULAR BIOAVAILABILITY.

  • Ophthalmology
  • APAC
  • North America
  • United States
  • World

Ocular' s hydrogel provides containment, localization and protection from inflammatory response, and a material for sustained delivery of drugs to the eye.

  • Eye Disease
  • Ophthalmology
  • United States
  • Company
  • Ocular Therapeutix, Inc.
  • ASSET PURCHASE

Ohr has a sustained-release micro-fabricated micro-particle ocular drug delivery platform technology that utilizes hydrogel template approach to prepare microparticles or other configurations.

  • Ophthalmology
  • United States
  • Company
  • Company Operations
  • Ohr Pharmaceutical Inc.
  • EQUITY OFFERING
  • LICENSING AGREEMENTS

Graybug Vision' s proprietary ocular drug delivery technologies enable the delivery of the compounds to the various compartments of the eye.

  • Ophthalmology
  • Pharmaceutical
  • United States
  • Company
  • Graybug Vision, Inc.
  • DEXAMETHASONE PHOSPHATE - DRUG PROFILE

EGP-## will be administered using the EyeGate II Ocular Drug Delivery System.

  • Eye Disease
  • Ophthalmology
  • United States
  • Product Initiative
  • EyeGate Pharmaceuticals, Inc.

EGP-## will be administered using the EyeGate II Ocular Drug Delivery System.

  • Biosimilar
  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • EyeGate Pharmaceuticals, Inc.

The drug candidates are developed based on sustained release microfabrication ocular drug delivery technology.

  • Eye Disease
  • Ophthalmology
  • United States
  • Product Initiative
  • Aldeyra Therapeutics, Inc.

Ocular' s hydrogel provides containment, localization and protection from inflammatory response, and a material for sustained delivery of drugs to the eye.

  • Ophthalmic Solution
  • Ophthalmology
  • Pharmaceutical
  • United States
  • Product Initiative

The company provides services such as drug formulations, drug delivery, drug discovery, clinical trials, ocular therapeutics, eye treatment services.

  • Medical Biotechnology
  • Ophthalmology
  • United States
  • Product Initiative
  • Galapagos NV

Graybug Vision' s proprietary ocular drug delivery technologies enable the delivery of the compounds to the various compartments of the eye.

  • Eye Disease
  • Ophthalmology
  • Pharmaceutical
  • United States
  • Aerie Pharmaceuticals, Inc.
  • GENE SIGNAL INTERNATIONAL SA
  • RETINAL VEIN OCCLUSION - PIPELINE BY GRAYBUG VISION INC, H1 2018

EGP-## will be administered using the EyeGate II Ocular Drug Delivery System.

  • Medical Biotechnology
  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • United States
  • SUSTAINED RELEASE OCULAR DRUG DELIVERY SYSTEMS: DISTRIBUTION BY SITE OF INTRAOCULAR PLACEMENT
  • SUSTAINED RELEASE OCULAR DRUG DELIVERY SYSTEMS: RESEARCH PROJECTS AT UNIVERSITIES

OCULAR DRUG DELIVERY SYSTEMS ##. ##. ##.

  • Ophthalmology
  • North America
  • United States
  • Allergan plc
  • Neurotech Pharmaceuticals, Inc.
  • GLAUKOS CORP
  • DRUGS FOR STEROID INDUCED GLAUCOMA - DRUG PROFILE

Graybug Vision' s proprietary ocular drug delivery technologies enable the delivery of the compounds to the various compartments of the eye.

  • Ophthalmology
  • United States
  • World
  • Company
  • Product Initiative
  • DRUG-ELUTING CONTACT LENSES PRODUCT OVERVIEW

Contact lenses have been studied as a means of ocular drug delivery for nearly ## years, yet many such lenses are ineffective because they dispense the drug too quickly.

  • Clinical Trial
  • Eye Disease
  • Eyewear
  • Ophthalmology
  • Valeant Pharmaceuticals International, Inc.
  • DIABETIC MACULAR EDEMA - PIPELINE BY FORMYCON AG, H1 2019
  • FORMYCON AG

EGP-## will be administered using the EyeGate II Ocular Drug Delivery System.

  • Medical Biotechnology
  • Ophthalmology
  • United States
  • Company
  • Product Initiative
  • FORMYCON AG
  • DIABETIC MACULAR EDEMA - PIPELINE BY GRAYBUG VISION INC, H2 2019

Graybug Vision' s proprietary ocular drug delivery technologies enable the delivery of the compounds to the various compartments of the eye.

  • Medical Biotechnology
  • Ophthalmology
  • United States
  • Product Initiative
  • Clearside Biomedical, Inc.
  • GENE SIGNAL INTERNATIONAL SA

GRAYBUG VISION' S PROPRIETARY OCULAR DRUG DELIVERY TECHNOLOGIES ENABLE THE DELIVERY OF THE COMPOUNDS TO THE VARIOUS COMPARTMENTS OF THE EYE.

  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • 5.2.24 GRAYBUG VISION INC
  • GLAUCOMA - PIPELINE BY GRAYBUG VISION INC, H2 2018

GRAYBUG VISION' S PROPRIETARY OCULAR DRUG DELIVERY TECHNOLOGIES ENABLE THE DELIVERY OF THE COMPOUNDS TO THE VARIOUS COMPARTMENTS OF THE EYE.

  • Eye Disease
  • Ophthalmology
  • Pharmaceutical
  • Type 2 Diabetes
  • Product Initiative
  • SMALL MOLECULE FOR DRY EYE - DRUG PROFILE

THE DRUG CANDIDATE IS DEVELOPED BASED ON EYESOL DRUG DELIVERY TECHNOLOGY WHICH COMPRISES OF SEMIFLUORINATED ALKANES (SFAS) AS DRUG DELIVERY MEDIUM.

  • Eye Disease
  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • Product Initiative
  • GENSIGHT BIOLOGICS SA
  • AGE RELATED MACULAR DEGENERATION - PIPELINE BY GRAYBUG VISION INC, H1 2018

Graybug Vision" s proprietary ocular drug delivery technologies enable the delivery of the compounds to the various compartments of the eye.

  • Eye Disease
  • Monoclonal Antibody
  • Ophthalmology
  • Pharmaceutical
  • Allergan plc
  • THE CURRENT CHALLENGES IN OPHTHALMOLOGY ARE TO DESIGN DRUGS WITH GREATER EFFICACY, MINIMALLY INVASIVE MODE OF ADMINISTRATION, AND LESS FREQUENT ADMINISTRATION
  • OPHTHALMOLOGY DRUGS WITH HIGHEST SALES IN THE 7MM

DRUG COMBINATIONS AND NOVEL OCULAR DRUG DELIVERY SYSTEMS Recent drug approvals for glaucoma have been dominated by fixed-dose combinations (FDCs) of existing therapies, positioned to help improve patient compliance.

  • Ophthalmology
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • BACK OF THE EYE: DRUG DELIVERY TECHNOLOGIES

OCULAR DRUG DELIVERY TECHNOLOGY (GRAYBUG VISION) Parameters Name of the Technology Developer (HQ) Type of Technology Mechanism of Action Details Ocular Drug Delivery Technology Graybug Vision (US) Drug Delivery Technology The te

  • Ophthalmology
  • United States
  • Alcon, Inc.
  • Allergan plc
  • Novartis AG

EGP-## will be administered using the EyeGate II Ocular Drug Delivery System.

  • Autoimmune Disease
  • Ophthalmology
  • United States
  • Product Initiative
  • Galapagos NV
  • DRUG-ELUTING CONTACT LENSES - PRODUCT DESCRIPTION

Contact lenses have been studied as a means of ocular drug delivery for nearly ## years, yet many such lenses are ineffective because they dispense the drug too quickly.

  • Medical Device
  • Ophthalmology
  • United States
  • Company
  • Valeant Pharmaceuticals International, Inc.

Ocular Immunology and Inflammatory; ##: ##-##.

  • Ophthalmology
  • AbbVie Inc.
  • Clearside Biomedical, Inc.
  • pSivida Corp.
  • Santen Pharmaceutical Co., Ltd.
  • FEATURED NEWS & PRESS RELEASES

ACIONT OFFERS SERVICES SUCH AS DRUG FORMULATIONS, DRUG DELIVERY, DRUG DISCOVERY, CLINICAL TRIALS, OCULAR THERAPEUTICS, AND EYE TREATMENT SERVICES.

  • Eye Disease
  • Ophthalmology
  • Therapy
  • United States
  • Product Initiative
  • DEXAMETHASONE ACETATE - DRUG PROFILE

EGP-## will be administered using the EyeGate II Ocular Drug Delivery System.

  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

One unit refers to one monofocal foldable intra ocular lens.

  • Ophthalmology
  • Latin America
  • Mexico
  • North America
  • Market Size

One unit refers to one monofocal foldable intra ocular lens.

  • Ophthalmology
  • Northern Europe
  • United Kingdom
  • Abbott Medical Optics, Inc.
  • Alcon, Inc.

One unit refers to one monofocal foldable intra ocular lens.

  • Ophtalmic Surgery Device
  • Ophthalmology
  • Canada
  • North America
  • Valeant Pharmaceuticals International, Inc.